Fortrea gains after $45 million deal for Worldwide Clinical Trials' early-stage services business

Fortrea Holdings

02/09/2026 12:51

** Shares of contract research organization Fortrea FTRE.O rise 1.2% to $17.94 premarket
** Co says it will acquire Worldwide Clinical Trials' Early Phase Services division in an all-cash transaction valued at about $45 million
** Says the business includes a 200-bed clinical pharmacology unit in San Antonio, a bioanalytical laboratory in Austin and a biospecimen storage facility in Texas
** FTRE says the acquisition adds in-house bioanalytical capabilities and expands its North American early-stage clinical research capacity
** Worldwide says the transaction will allow it to focus investments on its rapidly growing later-stage business in oncology, neuroscience, internal medicine and rare diseases
** Deal is expected to close after regulatory and licensing approvals
** As of last close, stock up ~3% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))